Wang et al. conducted a meta-analysis of the Oncomine databases to map the level of FGL1 in a series of solid tumors, and found FGL1 is highly expressed in lung cancer, prostate cancer, breast cancer, melanoma and colorectal cancer, but downregulated in pancreas cancer, head and neck cancers 8. The gene discussed is FGL1; the disease is colorectal cancer.